Evidence map›Paper›PMID 33801437›Full record

ArticleViruses2021

Infection of Chinese Rhesus Monkeys with a Subtype C SHIV Resulted in Attenuated In Vivo Viral Replication Despite Successful Animal-to-Animal Serial Passages.

Gerald K Chege, Craig H Adams, Alana T Keyser, Valerie Bekker, Lynn Morris, Francois J Villinger, Anna-Lise Williamson, Rosamund E Chapman

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Gerald K ChegePrimate Unit and Delft Animal Centre, Centre and Platform Office, South African Medical Research Council, Parow Valley, 7505 Cape Town, South Africa.ORCID 0000-0003-3986-9638
Craig H AdamsDivision of Medical Virology, Department of Pathology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, 7925 Cape Town, South Africa.
Alana T KeyserDivision of Medical Virology, Department of Pathology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, 7925 Cape Town, South Africa.
Valerie BekkerCentre for HIV and STIs, National Institute for Communicable Diseases, a Division of the National Health Laboratory Service, Sandringham, 2131 Johannesburg, South Africa.
Lynn MorrisCentre for HIV and STIs, National Institute for Communicable Diseases, a Division of the National Health Laboratory Service, Sandringham, 2131 Johannesburg, South Africa.ORCID 0000-0003-3961-7828
Francois J VillingerNew Iberia Research Center, University of Louisiana, Louisiana, LA 70560, USA.ORCID 0000-0002-7790-2008
Anna-Lise WilliamsonDivision of Medical Virology, Department of Pathology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, 7925 Cape Town, South Africa.ORCID 0000-0002-5467-1200
Rosamund E ChapmanDivision of Medical Virology, Department of Pathology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, 7925 Cape Town, South Africa.ORCID 0000-0001-9162-2099

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rhesus macaques can be readily infected with chimeric simian-human immunodeficiency viruses (SHIV) as a suitable virus challenge system for testing the efficacy of HIV vaccines. Three Chinese-origin rhesus macaques (ChRM) were inoculated intravenously (IV) with SHIVC109P4 in a rapid serial in vivo passage. SHIV recovered from the peripheral blood of the final ChRM was used to generate a ChRM-adapted virus challenge stock. This stock was titrated for the intrarectal route (IR) in 8 ChRMs using undiluted, 1:10 or 1:100 dilutions, to determine a suitable dose for use in future vaccine efficacy testing via repeated low-dose IR challenges. All 11 ChRMs were successfully infected, reaching similar median peak viraemias at 1-2 weeks post inoculation but undetectable levels by 8 weeks post inoculation. T-cell responses were detected in all animals and Tier 1 neutralizing antibodies (Nab) developed in 10 of 11 infected ChRMs. All ChRMs remained healthy and maintained normal CD4

Indexed as

Simian Acquired Immunodeficiency SyndromeAnimalsCell LineHumansMacaca mulattaSAIDS VaccinesSerial PassageSimian Immunodeficiency VirusViral LoadVirus ReplicationSAIDS VaccinesChinese rhesus macaquesSHIVsubtype C

Identifiers

PMID33801437
PMCPMC7998229

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.